1. Spagnolo P, Kropski JA, Jones MG, Lee JS, Rossi G, Karampitsakos T, et al. Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. Pharmacol Ther. 2021;222:107798 doi.org/10.1016/j.pharmthera.2020.107798.
2. Ma H, Wu X, Li Y, Xia Y. Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis. Front Pharmacol. 2022;13:963054 doi.org/10.3389/fphar.2022.963054.
3. Qian W, Xia S, Yang X, Yu J, Guo B, Lin Z, et al. Complex Involvement of the Extracellular Matrix, Immune Effect, and Lipid Metabolism in the Development of Idiopathic Pulmonary Fibrosis. Front Mol Biosci. 2021;8:800747 doi.org/10.3389/fmolb.2021.800747.
4. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941-52 doi.org/10.1016/s0140-6736(17)30866-8.
5. Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med. 2021;21(1):411 doi.org/10.1186/s12890-021-01783-1.
6. Gonzalez LL, Garrie K, Turner MD. Role of S100 proteins in health and disease. Biochim Biophys Acta Mol Cell Res. 2020;1867(6):118677 doi.org/10.1016/j.bbamcr.2020.118677.
7. Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;185(1):67-76 doi.org/10.1164/rccm.201101-0058OC.
8. Tanaka K, Enomoto N, Hozumi H, Isayama T, Naoi H, Aono Y, et al. Serum S100A8 and S100A9 as prognostic biomarkers in acute exacerbation of idiopathic pulmonary fibrosis. Respir Investig. 2021;59(6):827-36 doi.org/10.1016/j.resinv.2021.05.008.
9. Pietzsch J, Hoppmann S. Human S100A12: a novel key player in inflammation? Amino Acids. 2009;36(3):381-9 doi.org/10.1007/s00726-008-0097-7.
10. Zheng J, Dong H, Zhang T, Ning J, Xu Y, Cai C. Development and Validation of a Novel Gene Signature for Predicting the Prognosis of Idiopathic Pulmonary Fibrosis Based on Three Epithelial-Mesenchymal Transition and Immune-Related Genes. Front Genet. 2022;13:865052 doi.org/10.3389/fgene.2022.865052.
11. Kubo F, Ariestanti DM, Oki S, Fukuzawa T, Demizu R, Sato T, et al. Loss of the adhesion G-protein coupled receptor ADGRF5 in mice induces airway inflammation and the expression of CCL2 in lung endothelial cells. Respir Res. 2019;20(1):11 doi.org/10.1186/s12931-019-0973-6.
12. Tanaka N, Ikari J, Anazawa R, Suzuki M, Katsumata Y, Shimada A, et al. S100A12 inhibits fibroblast migration via the receptor for advanced glycation end products and p38 MAPK signaling. In Vitro Cell Dev Biol Anim. 2019;55(8):656-64 doi.org/10.1007/s11626-019-00384-x.
13. Bagheri V. S100A12 is not expressed in rodents: Transgenic mouse model is needed. Molecular Immunology. 2022;152:35 doi.org/https://doi.org/10.1016/j.molimm.2022.10.003.
14. Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):W216-w21 doi.org/10.1093/nar/gkac194.
15. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362-d8 doi.org/10.1093/nar/gkw937.
16. Kolde R, Laur S, Adler P, Vilo J. Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics. 2012;28(4):573-80 doi.org/10.1093/bioinformatics/btr709.
17. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-e47 doi.org/10.1164/rccm.202202-0399ST.
18. Wang J, Sun L, Nie Y, Duan S, Zhang T, Wang W, et al. Protein Kinase C δ (PKCδ) Attenuates Bleomycin Induced Pulmonary Fibrosis via Inhibiting NF-κB Signaling Pathway. Front Physiol. 2020;11:367 doi.org/10.3389/fphys.2020.00367.
19. Möller A, Jauch-Speer SL, Gandhi S, Vogl T, Roth J, Fehler O. The roles of toll-like receptor 4, CD33, CD68, CD69, or CD147/EMMPRIN for monocyte activation by the DAMP S100A8/S100A9. Front Immunol. 2023;14:1110185 doi.org/10.3389/fimmu.2023.1110185.
20. Farokhzadian J, Mangolian Shahrbabaki P, Bagheri V. S100A12-CD36 axis: A novel player in the pathogenesis of atherosclerosis? Cytokine. 2019;122:154104 doi.org/https://doi.org/10.1016/j.cyto.2017.07.010.
21. Wang J, Lai X, Yao S, Chen H, Cai J, Luo Y, et al. Nestin promotes pulmonary fibrosis via facilitating recycling of TGF-β receptor I. Eur Respir J. 2022;59(5) doi.org/10.1183/13993003.03721-2020.
22. Liu K, Liu D, Feng Y, Zhang H, Zeng D, Liu Q, et al. Spliceosome-associated protein 130: a novel biomarker for idiopathic pulmonary fibrosis. Ann Transl Med. 2020;8(16):986 doi.org/10.21037/atm-20-4404.
23. Wang F, Li P, Li FS. Integrated Analysis of a Gene Correlation Network Identifies Critical Regulation of Fibrosis by lncRNAs and TFs in Idiopathic Pulmonary Fibrosis. Biomed Res Int. 2020;2020:6537462 doi.org/10.1155/2020/6537462.
24. Butenko S, Satyanarayanan SK, Assi S, Schif-Zuck S, Sher N, Ariel A. Transcriptomic Analysis of Monocyte-Derived Non-Phagocytic Macrophages Favors a Role in Limiting Tissue Repair and Fibrosis. Front Immunol. 2020;11:405 doi.org/10.3389/fimmu.2020.00405.
25. Leurs P, Lindholm B. The AGE-RAGE pathway and its relation to cardiovascular disease in patients with chronic kidney disease. Arch Med Res. 2013;44(8):601-10 doi.org/10.1016/j.arcmed.2013.11.002.
26. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, et al. Cell migration: integrating signals from front to back. Science. 2003;302(5651):1704-9 doi.org/10.1126/science.1092053.
27. Li Y, He Y, Chen S, Wang Q, Yang Y, Shen D, et al. S100A12 as Biomarker of Disease Severity and Prognosis in Patients With Idiopathic Pulmonary Fibrosis. Front Immunol. 2022;13:810338 doi.org/10.3389/fimmu.2022.810338.
28. Simard JC, Cesaro A, Chapeton-Montes J, Tardif M, Antoine F, Girard D, et al. S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-κB(1.). PLoS One. 2013;8(8):e72138 doi.org/10.1371/journal.pone.0072138.
29. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol. 2003;170(6):3233-42 doi.org/10.4049/jimmunol.170.6.3233.
30. Wilkinson A, Kawaguchi N, Geczy C, Di Girolamo N. S100A8 and S100A9 proteins are expressed by human corneal stromal dendritic cells. Br J Ophthalmol. 2016;100(9):1304-8 doi.org/10.1136/bjophthalmol-2016-308827.
31. von Wulffen M, Luehrmann V, Robeck S, Russo A, Fischer-Riepe L, van den Bosch M, et al. S100A8/A9-alarmin promotes local myeloid-derived suppressor cell activation restricting severe autoimmune arthritis. Cell Rep. 2023;42(8):113006 doi.org/10.1016/j.celrep.2023.113006.
32. Palmer LD, Maloney KN, Boyd KL, Goleniewska AK, Toki S, Maxwell CN, et al. The Innate Immune Protein S100A9 Protects from T-Helper Cell Type 2–mediated Allergic Airway Inflammation. American Journal of Respiratory Cell and Molecular Biology. 2019;61(4):459-68 doi.org/10.1165/rcmb.2018-0217OC.
33. Aggarwal NR, King LS, D'Alessio FR. Diverse macrophage populations mediate acute lung inflammation and resolution. American Journal of Physiology - Lung Cellular and Molecular Physiology. 2014;306(8):L709-L25 doi.org/10.1152/ajplung.00341.2013.
34. Sun SN, Ni SH, Li Y, Liu X, Deng JP, Chen ZX, et al. G-MDSCs promote aging-related cardiac fibrosis by activating myofibroblasts and preventing senescence. Cell Death Dis. 2021;12(6):594 doi.org/10.1038/s41419-021-03874-7.
35. Zhong A, Xu W, Zhao J, Xie P, Jia S, Sun J, et al. S100A8 and S100A9 Are Induced by Decreased Hydration in the Epidermis and Promote Fibroblast Activation and Fibrosis in the Dermis. American Journal of Pathology. 2016;186(1):109-22 doi.org/10.1016/j.ajpath.2015.09.005.
36. Demirdöğen E, Görek Dilektaşlı A, Acet Öztürk NA, Yeşilbursa D, Budak F, Coşkun F, et al. Serum Krebs von den Lungen-6: promising biomarker to differentiate CPFE from IPF. Sarcoidosis Vasc Diffuse Lung Dis. 2022;39(4):e2022035 doi.org/10.36141/svdld.v39i4.11344.
37. Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology. 2006;11(2):164-8 doi.org/10.1111/j.1440-1843.2006.00834.x.